NCT05861635View on ClinicalTrials.gov

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

PHASE4RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2026

Conditions
Breast CancerNeoadjuvant Therapy
Interventions
DRUG

Disitamab Vedotin combined with Tislelizumab

"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"

Trial Locations (1)

430000

RECRUITING

WuhanHU, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER